Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein

Benjamin A. Krishna(Cleveland Clinic), John Sinclair(University of Cambridge), Mette M. Rosenkilde(University of Copenhagen), Sebastian Voigt(Robert Koch Institute), Katja Spieß(University of Copenhagen), Betty Lau(University of Cambridge), Thomas N. Kledal(Technical University of Denmark), Emma Poole(University of Cambridge)
Nature Communications
February 2, 2017
10.1038/ncomms14321
Cited by 80

Related Papers

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
|Nature|2020|1.4k
Cross-reactive CD4 <sup>+</sup> T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
|Science|2021|315
Defining the Transcriptional Landscape during Cytomegalovirus Latency with Single-Cell RNA Sequencing
|mBio|2018|184
Neurodevelopmental protein Musashi-1 interacts with the Zika genome and promotes viral replication
|Science|2017|181
Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
|BMC Pharmacology and Toxicology|2016|179